News
September 21, 2009 — CardiacAssist Inc. announced today that it will showcase transseptal puncture training simulation, developed by Mentice Inc., at its TandemHeart® System exhibit in San Francisco at the “Transcatheter Therapeutics (TCT) 2009” Annual Scientific Session next week.
September 21, 2009
News
September 21, 2009 – IBA (Ion Beam Applications S.A.), a provider of PET radiopharmaceuticals, and Aposense Ltd., a developer of agents targeting apoptosis (programmed cell death) for molecular imaging and therapy, today announced an exclusive collaboration agreement for commercializing Aposense [18F]–ML-10, Aposense’s novel agent for molecular imaging of apoptosis.
September 21, 2009
Technology
September 21, 2009 - Toshiba America Medical Systems Inc. introduced Low-Contrast Imaging (LCI) for Toshiba’s Infinix-i systems with mid (12 x12-inch) flat and large (12 x16-inch) flat-panel detectors (FPD), and will demonstrate its low-contrast imaging capabilities at this year’s Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco, Sept. 21 - Sept.
September 21, 2009Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
September 21, 2009 — Minnow Medical recently announced it will be presenting interim clinical data regarding a novel technology to treat Peripheral Artery Disease (PAD) on Monday, Sept. 21. The presentation, led by James R. Margolis will take place at 11:58 a.m. in room 133.
September 21, 2009
News
September 18, 2009 - A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia in a single examination, giving a better indication of clinically significant coronary artery disease, said a report appears in the September 15 issue of the Journa
September 18, 2009
News
September 18, 2009 – Patients’ response to anti-platelet therapy after percutaneous coronary intervention (PCI) and its impact on clinical outcomes will be covered in a TCT 2009 breakfast symposium starting at 6:30 a.m. Wedensday, Sept. 23 in room 121 at the Moscone Center in San Francisco.
September 18, 2009Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
Mount Sinai First In Nation to Ablate Atrial Fibrillation Using New Visually-Guided Balloon Catheter
September 18, 2009 – Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation (AF) using a visually-guided laser balloon catheter.
September 18, 2009News
September 18, 2009 – Boston Scientific today said it completed patient enrollment in the workhorse portion of its PLATINUM clinical program, a global, randomized, pivotal controlled trial designed to support FDA and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum-chromium PROMUS Element Everolimus-Eluting Coronary Stent System.
September 18, 2009
Technology
September 18, 2009 – The FDA has approved Valturna (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.
September 18, 2009Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News
September 18, 2009 – Following the recent CE mark certification of the vProtect Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and roundtable discussions on lesion-specific therapy for coronary artery disease at TCT 2009, Sept. 21-25, in San Francisco.
September 18, 2009
Feature | Dave Fornell
When vessels are stretched and ripped via angioplasty balloon expansion, the exposed soft muscle tissue can lead to the proliferation of scar tissue (neointimal hyperplasia) that can reocclude the vessel. Drug-eluting stents (DES) were introduced in 2003 to overcome this issue with anti-proliferative drugs, the same as used to prevent cellular growth in cancerous tumors.
September 17, 2009
Feature | Dave Fornell
There is a growing trend in electrophysiology toward remote, home monitoring of implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers and implantable cardiac monitors (ICMs).
September 17, 2009Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Feature | Richard R. Rogoski
A trend that was fueled by cardiologists wanting to gain a larger share of reimbursement fees, while at the same time providing more personalized care to their patients, is beginning to fizzle as reimbursements continue to be cut.
September 17, 2009
Feature | Dave Fornell
Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high restenosis rate of between 30-40 percent. The cobalt-chromium or stainless steel stents helped reduce restenosis, bringing rates down to about 15-20 percent, but BMS also increased the risk of early in-stent thrombosis shortly following the procedure.
September 17, 2009
News
September 18, 2009 ¬– Abbott has announced the company's schedule of key news announcements and events during the Transcatheter Cardiovascular Therapeutics (TCT) 2009 conference in San Francisco, Sept. 21-25.
September 17, 2009© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now